BIONANO GENOMICS


Associated tags: Software, Spectrum, Patient, OGM, Biology, Genome, Medicine, SAN, Genomics, Doctor of Philosophy, Research

Locations: SWITZERLAND, MASSACHUSETTS, HAMILTON, NEVADA, LONG, UNITED STATES, UKRAINE, RUSSIA, GEORGIA, SPAIN, LOS ANGELES, RENO, NEW YORK CITY, ISRAEL, SAN DIEGO, CA, US, BEIJING, NEW YORK, CHINA, FLORIDA

Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Featuring OGM Utility Across a Broad Range of Research Applications

Retrieved on: 
Monday, March 13, 2023
Disease, DRS, DSM-IV codes, LGG, Research, Columbia University, Fragile X syndrome, Convention, ACMG, Medical genetics, SVS, American College, American College of Medical Genetics and Genomics, SAN, OGM, Augusta University, Pharmaceutical industry, Vaccine, Genomics

ACMG’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in clinical genetics research.

Key Points: 
  • ACMG’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in clinical genetics research.
  • The ACMG conference will be held March 14-18, 2023, in Salt Lake City, Utah.
  • Three leaders in clinical research will participate in a sponsored session highlighting the use of OGM in prenatal and postnatal genetic analysis.
  • Dr. Brynn Levy of Columbia University will present findings from two comprehensive multi-site studies comparing OGM to traditional cytogenetic methods for prenatal and postnatal analysis.

Bionano Genomics Reports Fourth Quarter and Full-Year 2022 Results and Provides Revenue Outlook for 2023

Retrieved on: 
Thursday, March 9, 2023
Partnership, Myelodysplastic syndrome, MDS, Acquisition, MD Anderson Cancer Center, Cell, Bone marrow, LDT, Standard of care, SAN, CRISPR, Research, DNA, Acute myeloid leukemia, Genomics, Cancer, Growth, Karyotype, Genetic disorder, University, European, DSM-IV codes, GAAP, Regenerative medicine, UHMW, Workflow, Doctor of Philosophy, Chromosome, ITP, SOC, Data analysis, OGM, Sale, AML, Video game, Renewable energy, Clothing, Cryptocurrency, Dietary supplement, Medical device, Fine chemical, Vaccine, Pharmaceutical industry, Satellite navigation device

“Bionano issued revenue guidance for the first time in 2022, and we exceeded our total 2022 guidance range.

Key Points: 
  • “Bionano issued revenue guidance for the first time in 2022, and we exceeded our total 2022 guidance range.
  • Total revenue for the fourth quarter of 2022 was $8.2 million, an increase of 14% compared to $7.2 million in the third quarter of 2022 and an increase of 30% compared to the fourth quarter of 2021.
  • Gross margin for the fourth quarter of 2022 was 22%, compared to 4% from the fourth quarter of 2021.
  • Fourth quarter 2022 non-GAAP operating expense was $30.6 million, compared to $21.8 million in the fourth quarter of 2021.

Bionano Announces Two Publications from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing including the First Peer-Reviewed Publication on the Multi-Site Evaluation of OGM Against SOC

Retrieved on: 
Thursday, March 2, 2023
DSM-IV codes, SOC, Doctor of Philosophy, Spectrum, Phenotype, Genomics, Clinical trial, OGM, University, University of Rochester, Polyploidy, Workflow, FMR1, Patient, Aneuploidy, SVS, Medical college, Genetic disorder, FACMG, Standard of care, Publication, SAN, University of Rochester Medical Center, Diagnosis, Chromosomal translocation, CNV, ASD, Intellectual disability, AOH, Dietary supplement, Pharmaceutical industry, Medical device, Mail order, Cryptocurrency, Genetic distance, 7p22.1 microduplication syndrome

describes the multi-site evaluation of optical genome mapping (OGM) for postnatal genetic disorders with 404 samples and shows:

Key Points: 
  • describes the multi-site evaluation of optical genome mapping (OGM) for postnatal genetic disorders with 404 samples and shows:
    Pre-print publication from Broeckel, et al.
  • The clinical trial is designed to compare OGM to SOC, including concordance, reproducibility, technical success rate and the rate of detecting reportable findings in cases.
  • A peer-reviewed publication covered an interim readout of the study, which showed OGM’s high technical performance and reproducibility across sites versus SOC analysis.
  • Key findings were reported as follows:
    The pre-print publication describes OGM performance metrics compared to SOC methods for challenging samples from diagnosed and undiagnosed rare diseases.

Bionano to Report Fourth Quarter and Year End 2022 Financial Results and Host a Conference Call and Webcast March 9, 2023

Retrieved on: 
Wednesday, March 1, 2023
Telephone, ID, Webcast, Online shopping, Internet service provider, Security (finance)

Participants may access a live webcast of the call on the Investors page of the Bionano website.

Key Points: 
  • Participants may access a live webcast of the call on the Investors page of the Bionano website.
  • To participate via telephone, please register in advance at this link.
  • Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
  • A replay of the conference call and webcast will be archived on Bionano’s investor relations website at https://ir.bionanogenomics.com/ for at least 30 days.

Bionano to Present at the 43rd Annual Cowen Healthcare Conference

Retrieved on: 
Monday, February 27, 2023
SAN, Genomics, Conference, Management, Online shopping, Cryptocurrency

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that company management will present at the 43rd Annual Cowen Healthcare Conference.

Key Points: 
  • SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that company management will present at the 43rd Annual Cowen Healthcare Conference.
  • Erik Holmlin, Ph.D., Bionano’s president and chief executive officer, is scheduled to present a corporate overview on Monday, March 6th, 2023 at 1:30 pm ET.
  • A live webcast of the presentation will be available to view on the Events page in the Investors section of Bionano’s website.

Bionano Announces China NMPA Approval for DNA Extraction and Labeling Products for IVD Use in Hematologic Malignancies

Retrieved on: 
Wednesday, February 22, 2023
BGPT, Doctor of Philosophy, DNA, Genomics, BMA, OEM, SAN, OGM, DLS, National Medical Products Administration, NMPA, Management

NMPA issued three approvals to BGPT: two for Bionano’s direct label and stain (DLS) DNA labeling kits and one for Bionano’s bone marrow aspirate (BMA) DNA isolation kit.

Key Points: 
  • NMPA issued three approvals to BGPT: two for Bionano’s direct label and stain (DLS) DNA labeling kits and one for Bionano’s bone marrow aspirate (BMA) DNA isolation kit.
  • The NMPA registrations for Bionano’s products enable these reagents to be used for in vitro diagnostics in China.
  • Eventually, they are expected to help sales and placements of both Bionano’s instruments and reagents in China.
  • Obtaining the NMPA Class I certificate is only a starting point,” stated Ye Feng, PhD, president and chief executive officer of BGPT.

Bionano Shares Overview of AGBT Pre-Conference Workshop Program Along with Details of Company’s Innovative Research Grant Opportunity

Retrieved on: 
Tuesday, February 14, 2023
MBA, DNA, Medicine, SV, Genomics, Q&A, Acceleration, Workflow, Data analysis, Classification, NVIDIA, News, Software, University, Research, Bone marrow, University of Toronto, University Health Network, FACMG, Mass meeting, Disease, SAN, SVS, OGM, VIA, ITP, DSM-IV codes, DRS, Cancer, Doctor of Philosophy, Management

Bionano launched a grant opportunity designed to further transformational research involving SVs using OGM technology: Dr. Purim shared details of Bionano’s new grant program, which will award five prizes to researchers across a variety of research areas.

Key Points: 
  • Bionano launched a grant opportunity designed to further transformational research involving SVs using OGM technology: Dr. Purim shared details of Bionano’s new grant program, which will award five prizes to researchers across a variety of research areas.
  • “Bionano was pleased to sponsor the pre-conference workshop at AGBT, where we shared product development plans, news about our strategic collaboration with NVIDIA and an announcement of our Bionano Innovator Research Grant.
  • Smith and Hoischen in our program, where they presented details of innovative research and data analysis they have conducted utilizing Bionano technology.
  • A live webcast of the workshop is available here: https://bionano.com/agbt2023/ More details about the Bionano Innovator Research Grant opportunity can be found here: www.bionano.com/innovatorgrant
    Research areas for consideration include:

Bionano Strategy Day Highlighted the Company’s Strategic Initiatives and Growth Plans as well as OGM’s Competitive Value for Cell Bioprocessing, and Cancer and Genetic Disease Research

Retrieved on: 
Thursday, February 9, 2023
Health, MD, Genomics, OGM, Sanford Burnham Prebys Medical Discovery Institute, Cancer, Hospital, DRS, University of Toronto, NGS, Laboratory, University Health Network, University, Q&A, Cowen Inc., SAN, Medical College of Georgia, Cowen, Children's Hospital Los Angeles, MD Anderson Cancer Center, Workflow, Strategy, Doctor of Philosophy, FACMG, Management, Pharmaceutical industry, Microscope, Research

Bionano outlined the aim to transform cytogenetic analysis for cancer and genetic disease research through its digital workflow, which can provide increased resolution and success rates compared to traditional cytogenetic methods.

Key Points: 
  • Bionano outlined the aim to transform cytogenetic analysis for cancer and genetic disease research through its digital workflow, which can provide increased resolution and success rates compared to traditional cytogenetic methods.
  • Presentations also addressed plans to seek regulatory approval for certain of the company’s products, as well as reimbursement for OGM-based laboratory developed tests.
  • We were pleased with the participation from researchers and clinicians who see the benefits of OGM in their work.
  • A copy of the Strategy Day presentation can be viewed on the Investor Relations page on the company’s website at https://ir.bionanogenomics.com/.

Bionano’s Symposium 2023 Featured Record Numbers of Presentations Demonstrating Applications of OGM Across Cell Bioprocessing and Constitutional Genetic Disease and Cancer Research

Retrieved on: 
Thursday, February 2, 2023
Columbia University Irving Medical Center, Disease management, Research, MD Anderson Cancer Center, Genomics, KT, Chromosome, SNV, OGM, Cancer, Multiple myeloma, SVS, FISH, HRD, TNBC, Curie Institute (Paris), Fluorescence, Hospital, Poster, WGS, University, Harvard Medical School, Medical college, Genome, NGS, Laboratory, Breast, Augusta University, SAN, Quality control, Potency (pharmacology), Neoplasm, Clinical trial, T-cell lymphoma, Sheba Medical Center, Workflow, Medical College of Georgia, Whole genome sequencing, Karyotype, In situ hybridization, Doctor of Philosophy, FACMG, Pharmaceutical industry, Medical device, Medical imaging, Vaccine, Microscope, Brigham, Genentech, VIA

During this four-day online event, presenters reported on their use of OGM for applications in genetic disease, cancer and cell bioprocessing.

Key Points: 
  • During this four-day online event, presenters reported on their use of OGM for applications in genetic disease, cancer and cell bioprocessing.
  • OGM was highlighted by researchers as a high-performance, one-stop platform, potentially eliminating the need for multiple sequential testing.
  • Aside from high concordance with classical cytogenetic methods, OGM produced additional relevant findings in 52% of all analyzed samples.
  • (Day 2)
    OGM has additional potential applications, including cell bioprocessing QC, in academic and commercial laboratory settings.

Bionano Laboratories Expands its Clinical Testing Menu with Launch of its First OGM-Based Laboratory Developed Test (LDT) for Hematological Malignancies

Retrieved on: 
Tuesday, January 24, 2023
AML, Disease, Malignancy, Diagnosis, OGM, ALL, Blood, Biomarker, SVS, Myelodysplastic syndrome, Bone marrow, B-cell lymphoma, Chronic lymphocytic leukemia, CLL, Genome, Facioscapulohumeral muscular dystrophy, Lymphatic system, MDS, Patient, SAN, CML, FSHD, Workflow, LDT, Acute lymphoblastic leukemia, Acute myeloid leukemia, Pharmaceutical industry

OGM-Dx HemeOne is the second OGM-based LDT launched by Bionano Laboratories, following the laboratory’s LDT for facioscapulohumeral muscular dystrophy (FSHD), which was released in September 2022.

Key Points: 
  • OGM-Dx HemeOne is the second OGM-based LDT launched by Bionano Laboratories, following the laboratory’s LDT for facioscapulohumeral muscular dystrophy (FSHD), which was released in September 2022.
  • “We are pleased to see the launch of Bionano Laboratories' LDT for heme malignancies, which can assist patients in their diagnostic and prognostic journey.
  • Our laboratory’s robust LDT validation is designed to provide a comprehensive evaluation of genome wide SVs that will allow oncologists to assess the best potential therapies for their malignancy patients.
  • We believe the continued development of OGM-based LDTs will allow Bionano Laboratories to help create a roadmap for how OGM might be leveraged in a clinical setting,” stated Justin Leighton, vice president of laboratory business at Bionano Laboratories.